Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

This study aims to test plasma exposure to PF-05089771 with same formulation will be used for phase II trials (capsule).

Phase 1

Pfizer